(Q34437724)

2 August 2017

1 reference

title

Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents (English)

1 reference

2 August 2017

1 reference

1 reference

Cheer SM

1

1 reference

2 August 2017

Figgitt DP

series ordinal

2

1 reference

2 August 2017

language of work or name

1 reference

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

3

1 reference

2 August 2017

763-781

1 reference

2 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.2165/00128072-200103100-00004

2 August 2017

0 references

cites work

Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine?

1 reference

12 December 2020

Preclinical evidence on the psychotropic profile of fluvoxamine

1 reference

12 December 2020

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

12 December 2020

Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

12 December 2020

Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers.

1 reference

12 December 2020

A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers

1 reference

12 December 2020

Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder

1 reference

12 December 2020

Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain

1 reference

12 December 2020

Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*

1 reference

12 December 2020

Review of the animal pharmacology and pharmacokinetics of fluvoxamine

1 reference

12 December 2020

Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro

1 reference

12 December 2020

Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study

1 reference

12 December 2020

Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

1 reference

12 December 2020

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans

1 reference

12 December 2020

Clinical pharmacokinetics of fluvoxamine

1 reference

12 December 2020

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

1 reference

12 December 2020

Antidepressants and serotonin neurons of the raphe

1 reference

12 December 2020

Obsessive-compulsive disorder in children and adolescents. Clinical guidelines

1 reference

12 December 2020

Obsessive-compulsive disorder in children and adolescents

1 reference

12 December 2020

Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial

1 reference

12 December 2020

Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoin

1 reference

12 December 2020

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro

1 reference

12 December 2020

Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient

1 reference

12 December 2020

Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness

1 reference

12 December 2020

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder

1 reference

12 December 2020

Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors

1 reference

12 December 2020

Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo

1 reference

12 December 2020

Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function

1 reference

12 December 2020

Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness

1 reference

12 December 2020

Fluvoxamine increases the clozapine serum levels significantly

1 reference

12 December 2020

Comparison of the (pro)convulsive properties of fluvoxamine and clovoxamine with eight other antidepressants in an animal model

1 reference

12 December 2020

Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.

1 reference

12 December 2020

Treatment of anxiety disorders of childhood

1 reference

12 December 2020

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

12 December 2020

Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience

1 reference

12 December 2020

Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design

1 reference

12 December 2020

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

1 reference

12 December 2020

The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy

1 reference

12 December 2020

In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine

1 reference

12 December 2020

Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder

1 reference

12 December 2020

Pharmacotherapy in children and adolescents with obsessive-compulsive disorder.

1 reference

12 December 2020

A Risk-Benefit Assessment of Pharmacotherapy for Anxiety Disorders in Children and Adolescents

1 reference

12 December 2020

Fluvoxamine-induced theophylline toxicity

1 reference

12 December 2020

Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor

1 reference

12 December 2020

Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience.

1 reference

12 December 2020

A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers

1 reference

12 December 2020

Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness

1 reference

12 December 2020

Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study

1 reference

12 December 2020

Serotonin-selective antidepressants.

1 reference

12 December 2020

Fluvoxamine-Clozapine Drug Interaction: Inhibition In Vitro of Five Cytochrome P450 Isoforms Involved in Clozapine Metabolism

1 reference

12 December 2020

Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. American Academy of Child and Adolescent Psychiatry

1 reference

12 December 2020

Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole

1 reference

12 December 2020

Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents

1 reference

12 December 2020

Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs.

1 reference

12 December 2020

Probable metabolic interaction between methadone and fluvoxamine in addict patients

1 reference

12 December 2020

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

12 December 2020

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

12 December 2020

[3H]8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT1A binding site in the rat striatum

1 reference

12 December 2020

The effect of antidepressants on aversive periaqueductal gray stimulation in rats.

1 reference

12 December 2020

Elevated plasma levels of clozapine after concomitant use of fluvoxamine

1 reference

12 December 2020

Drug treatment of anxiety disorders in children

1 reference

12 December 2020

Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

12 December 2020

Toxic effects of theophylline caused by fluvoxamine

1 reference

12 December 2020

Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine

1 reference

12 December 2020

Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration

1 reference

12 December 2020

Increased trimipramine plasma levels during fluvoxamine comedication

1 reference

12 December 2020

Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine

1 reference

12 December 2020

Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.

1 reference

12 December 2020

A double-blind placebo-controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers

1 reference

12 December 2020

Acute effects of atypical antidepressants on various receptors in the rat brain.

1 reference

12 December 2020

Inhibition of imipramine N-demethylation by fluvoxamine in Chinese young men

1 reference

12 December 2020

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

1 reference

12 December 2020

Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients

1 reference

12 December 2020

Non-linear fluvoxamine disposition

1 reference

12 December 2020

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

12 December 2020

Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents

1 reference

12 December 2020

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

1 reference

12 December 2020

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

12 December 2020

Overview of the pharmacokinetics of fluvoxamine

1 reference

12 December 2020

Fluvoxamine-methadone interaction.

1 reference

12 December 2020

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study

1 reference

12 December 2020

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.

1 reference

12 December 2020

Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review

1 reference

12 December 2020

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial

1 reference

12 December 2020

A fluvoxamine-caffeine interaction study

1 reference

12 December 2020

Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients

1 reference

12 December 2020

The treatment of anxiety disorders in children and adolescents

1 reference

12 December 2020

Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder

1 reference

12 December 2020

10.2165/00128072-200103100-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference